Cellectis S.A. (NASDAQ:CLLS) Short Interest Up 107.2% in March

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 455,900 shares, a growth of 107.2% from the March 15th total of 220,000 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average trading volume of 369,300 shares, the short-interest ratio is presently 1.2 days.

Cellectis Price Performance

NASDAQ:CLLS traded down $0.07 during mid-day trading on Monday, reaching $1.38. 25,769 shares of the company were exchanged, compared to its average volume of 145,325. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $76.71 million, a PE ratio of -1.06 and a beta of 3.22. Cellectis has a 12 month low of $1.10 and a 12 month high of $3.38. The company has a fifty day moving average of $1.33 and a 200 day moving average of $1.63.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million. On average, research analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Cellectis from a "buy" rating to a "hold" rating in a research report on Thursday.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in shares of Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after buying an additional 12,500 shares during the period. Millennium Management LLC acquired a new position in shares of Cellectis in the 4th quarter valued at $962,000. Finally, B Group Inc. bought a new position in shares of Cellectis in the 4th quarter worth $5,547,000. Institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.